← Back to Search

Cancer Vaccine

Vaccine Therapy for Melanoma

Phase 2

Waitlist Available

Research Sponsored by CancerVax Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed malignant melanoma

At least 1 in-transit skin lesion measuring 3-10 mm in the longest diameter

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying a vaccine made from tumor cells to treat patients with malignant melanoma.

Who is the study for?

This trial is for adults aged 18 to 80 with malignant melanoma, specifically those who have at least one skin lesion between 3-10 mm. It's not specified who can't join the trial.Check my eligibility

What is being tested?

The study is testing a vaccine therapy on patients with malignant melanoma. The goal is to see if the vaccine helps the body's immune system destroy cancer cells effectively.See study design

What are the potential side effects?

Potential side effects are not detailed in this summary, but generally, vaccines may cause reactions at the injection site, flu-like symptoms, and allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is a confirmed malignant melanoma.

Select...

I have a skin lesion between 3-10 mm in size.

Select...

I am between 18 and 80 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

CancerVax CorporationLead Sponsor

2 Previous Clinical Trials

1,788 Total Patients Enrolled

Linda StrauseStudy ChairCancerVax Corporation

Media Library

Vaccine Therapy (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00128583 — Phase 2

Skin Cancer Clinical Trial 2023: Vaccine Therapy Highlights & Side Effects. Trial Name: NCT00128583 — Phase 2

Vaccine Therapy (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00128583 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the safety profile of this treatment?

"At Power, we rate the safety of this Phase 2 trial as a 2. While there is some data suggesting that the treatment is safe, there is no evidence to support its efficacy."

Answered by AI

Are there any other hospitals participating in this research?

"There are 12 sites where this clinical trial is currently enrolling patients. These locations include H. Lee Moffitt Cancer Center and Research Institute at University of South Florida in Tampa, Florida, CCOP - Dayton in Dayton, Ohio, and Simmons Cancer Center at University of Texas Southwestern Medical Center at Dallas in Dallas, Texas."

Answered by AI

Could you please inform me if this trial is available to patients who are under 30 years old?

"The minimum age for participation in this trial is 18 years old, while the maximum age limit is set at 80."

Answered by AI

Are there any open positions for individuals in this particular clinical trial?

"Unfortunately, this particular trial is not currently looking for new patients. Although, it should be noted that there are 788 other trials with open recruitment at the moment. This study was first posted on July 1st, 2005 and had its last edit on December 18th, 2013."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Therapy in Treating Patients With Malignant Melanoma

2005. "Vaccine Therapy in Treating Patients With Malignant Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00128583.

All > Malignant Melanoma